Pulse Biosciences, Inc.
PLSEHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframePulse Biosciences, Inc. operates as a novel bioelectric medicine company. With a market capitalization of $1.89B, it sits in small-cap territory. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians.
Market Cap
$1.89B
Beta
1.65
P/E (TTM)
—
P/E (Fwd)
-25.12
EPS (TTM)
$-1.10
EPS (Fwd)
$-1.09
ROE
-80.7%
ROA
-45.0%
Cash
$68.3M
Total Debt
$7.2M
Free CF
-$29.1M
52W Change
75.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $68.3M in cash comfortably exceeding the $7.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$29.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -80.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $700K (2022) to $350K (2025), a 50% decline worth watching.
With a beta above 1.5, PLSE tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PLSE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.